Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.44 |
| ▸ | ITGAV | P06756 | 17/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.44 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804884 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6809449 | 0.88 | ITGB3 (0.44) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6804856 | 0.87 | ITGB3 (0.42) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| Trifluoroacetic Acid SCHEMBL6809448 | 0.86 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6802895 | 0.85 | ITGB3 (0.40) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6799591 | 0.85 | ITGB3 (0.44) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6809710 | 0.80 | ITGB3 (0.38) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6810050 | 0.79 | SMN1; SMN2 (0.43) | ITGB3ITGAVITGB1ITGB5ITGB6 | |
| SCHEMBL6800561 | 0.78 | SMN1; SMN2 (0.40) | L3MBTL1 | |
| SCHEMBL6800874 | 0.78 | ITGB3 (0.56) | ITGB3ITGAVITGB1ITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1313705-A1 | GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6531494-B1 | Gem-substituted αvβ3 antagonists | PHARMACIA CORPORATION | 2003-03-11 | — | — | US | disclosed |
| WO-2002018340-A1 | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043994-A1 | Gem-substituted alpha v beta 3 antagonists | CACNG5, ITGAV, ITGA5 | ITGB3 4/4885ITGAV 2/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.